DHR vs HBIO · P/E 39, rev $6.26B vs rev $22.7M
Danaher Corporation (DHR) versus Harvard Bioscience Inc (HBIO) — a side-by-side from cached financials, not a winner call.
Danaher Corporation (DHR) is a diagnostics & research company listed on US. It is led by Rainer M. Blair.
Harvard Bioscience Inc (HBIO) is a medical instruments & supplies company listed on US.
Latest reported DHR revenue for 2026-06-26 was $6.26B. Net income was $870.0M. Revenue was up 5.3% from 2026-03-27 to 2026-06-26. DHR currently screens at market cap $144.18B and trailing P/E 39.0.
Latest reported HBIO revenue for 2026-06-30 was $22.7M. Net income was -$2.9M. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. HBIO currently screens at market cap $20.3M.
DHR currently screens at market cap $144.18B and trailing P/E 39.0. HBIO currently screens at market cap $20.3M.
Not investment advice. Open the DHR and HBIO stock pages for the full models.
Not investment advice.